LGALS3 and chronic kidney disease: A recent phase II study comparing treatment with a Gal-3 inhibitor (GCS-100) and a placebo in patients with CKD stage 3b showed that Gal-3 inhibition improved the glomerular filtration rate (unpublished data, ClinicalTrials.gov Identifier: NCT01843790).